Gene therapy offers hope for rare eye disease
NCT ID NCT06196827
First seen Mar 16, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This early-stage study tests a gene therapy called LX101 for people with a rare inherited eye disease that causes vision loss. The therapy uses a harmless virus to deliver a working copy of the RPE65 gene to the retina. Nine participants aged 6 and older will be monitored for safety and any improvement in vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DYSTROPHY ASSOCIATED WITH RPE65 MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, China
-
Shanghai General Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.